Aurinia Pharmaceuticals Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Aurinia Pharmaceuticals Inc.
The French drug maker isn’t moving its mRNA COVID-19 vaccine into Phase III, instead focusing on a GSK-partnered protein SARS-CoV-2 vaccine and applying mRNA technology elsewhere.
The Phase III PROpel study has shown that a combination of AstraZeneca's Lynparza and Johnson & Johnson's Zytiga significantly delayed disease progression as a first-line treatment for men with metastatic castration-resistant prostate cancer.
The company will focus on developing its VenoValve system to treat chronic venous insufficiency and a second product for venous disease.
From clinical trials to in-person sales calls, the pharmaceutical value chain has been tested by the COVID-19 pandemic, but has held up. Nevertheless, recent friction within this chain may be more than a passing irritation.
- Other Names / Subsidiaries
- Alberta Ltd.
- Isotechnika Pharma Inc.
- Thunderbolt Pharma, Inc.